髓过氧化物酶对体外肿瘤模型中低分子量肝素和利伐沙班抗凝活性的影响
该体外研究探讨髓过氧化物酶(MPO)对利伐沙班、达肝素和亭扎肝素抗凝活性的影响。三种抗凝药均抑制22Rv1细胞诱导的凝血酶生成、纤维蛋白凝块形成和血小板聚集;MPO预处理部分减弱达肝素和亭扎肝素谷浓度的抗凝活性,但不影响利伐沙班。MPO释放可能部分减弱达肝素和亭扎肝素谷浓度在副肿瘤白细胞活化背景下的抗凝活性,但此效应可能不足以解释利伐沙班在癌症相关血栓治疗中更优的疗效。
要点
- 三种抗凝药均抑制22Rv1细胞诱导的凝血酶生成、纤维蛋白凝块形成和血小板聚集。
- MPO预处理部分减弱达肝素和亭扎肝素谷浓度的抗凝活性,但不影响利伐沙班。
- MPO效应不依赖其催化特性,而需其结构完整性,热变性可消除该效应。
核心结论
- MPO释放可能部分减弱达肝素和亭扎肝素谷浓度在副肿瘤白细胞活化背景下的抗凝活性。
- 此效应可能不足以解释利伐沙班及其他口服Xa因子抑制剂在癌症相关血栓治疗中更优的疗效。
研究设计与样本
- 概念验证性体外研究,研究利伐沙班、达肝素和亭扎肝素在峰浓度和谷浓度下对肿瘤细胞诱导的促凝血活性和血小板聚集的影响,设有或无MPO条件,并用LPS或PMA刺激全血产生促炎条件后测定血浆上清凝血酶生成。
主要发现
- 三种抗凝药均抑制组织因子表达的前列腺癌细胞系22Rv1诱导的凝血酶生成、纤维蛋白凝块形成和血小板聚集。
- MPO预处理部分减弱达肝素和亭扎肝素谷浓度的抗凝活性,但不影响利伐沙班。
- MPO效应不涉及酶的催化特性,而需要其结构完整性,热变性后该效应消失。
- LPS或PMA刺激全血所得血浆中,MPO抗原水平升高与亭扎肝素抑制22Rv1诱导凝血酶生成的能力呈负相关。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Inflammation with leukocyte activation is a hallmark of cancer-associated thrombosis (CAT), and elevated leukocytes predict venous thromboembolism in cancer outpatients. In a recent trial, rivaroxaban was more efficacious than dalteparin in preventing CAT recurrence. OBJECTIVES: In a proof-of-concept study, we aimed to provide a mechanistic basis for improved efficacy of rivaroxaban compared to low molecular weight heparin in CAT treatment. METHODS: We studied the effects of rivaroxaban, dalteparin, and tinzaparin at peak and trough levels on tumor cell-induced procoagulant activity and platelet aggregation in the presence or absence of the cationic leukocyte-derived enzyme, myeloperoxidase (MPO). Furthermore, pro-inflammatory conditions were generated by stimulating whole blood with lipopolysaccharide (LPS) or phorbol-myristate-acetate (PMA), before measuring thrombin generation in plasma supernatants. RESULTS: All three anticoagulants inhibited thrombin generation, fibrin clot formation, and platelet aggregation induced by the tissue factor-expressing prostate carcinoma cell line, 22Rv1. Pre-incubation with MPO partially attenuated the anticoagulant activity of dalteparin and tinzaparin, but not rivaroxaban, at trough levels. The effect of MPO did not involve the enzyme's catalytic properties, but required its structural integrity, as indicated by heat denaturation. In plasma obtained from LPS- or PMA-stimulated whole blood, elevated MPO antigen levels inversely correlated with the ability of tinzaparin to inhibit 22Rv1-induced thrombin generation. CONCLUSIONS: Myeloperoxidase release may partially attenuate the anticoagulant activity of trough levels of dalteparin and tinzaparin in the context of paraneoplastic leukocyte activation. However, this effect is likely not sufficient to explain the improved efficacy of rivaroxaban, and possibly other oral factor Xa inhibitors, in CAT treatment.
引用
- Voigtlaender M, Beckmann L, Schulenkorf A, et al. Effect of myeloperoxidase on the anticoagulant activity of low molecular weight heparin and rivaroxaban in an in vitro tumor model. J Thromb Haemost. 2020. PMID: 32865287. doi:10.1111/jth.15075
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。